Recognizing that only 30-35% of HER2/neu positive patients respond to Herceptin, we publish the Cancer.gov database from time to time.
Two of our members, Barbara Bradfield and Ginger Empey had enrolled in the Phase I and Phase III trials of Herceptin and are still in remission today.
http://www.clinicaltrials.gov/ct/sea...&submit=Search
Warmest Regards
Joe